{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:25:42Z","timestamp":1791048342646,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Complete response (CR) is an important treatment goal in follicular lymphoma (FL). In relapsed or refractory (R\/R) FL, CR rates decline, and disease progression accelerates with each treatment line, with particularly poor outcomes in patients with high\u2010risk features. Odronextamab, a CD20\u2009\u00d7\u2009CD3 bispecific antibody, demonstrated deep, durable responses and generally manageable safety in R\/R FL in the Phase 2 ELM\u20102 study (NCT03888105); we present an exploratory analysis in patients who attained a CR. Patients received intravenous odronextamab with step\u2010up dosing in Cycle 1, 80\u2009mg weekly in Cycles 2\u20134, then 160\u2009mg once every 2 weeks until disease progression or other protocol\u2010defined reason for discontinuation. Patients with CR lasting \u22659 months switched to dosing once every 4 weeks. Overall, 73.4% (94\/128) of patients attained CR, 93.6% (88\/94) by first response assessment (~Week 12). Median time to CR was 2.7 months (range 2.3\u20137.9). Median duration of CR was 25.1 months (95% confidence interval [CI] 20.5\u2013not evaluable [NE]) overall and 23.7 months (18.2\u2013NE) in patients with high\u2010risk features. Overall, 79.5% (35\/44) of patients who switched to Q4W dosing maintained CR at last assessment. Patients with low\/undetectable CD20 expression by immunohistochemistry (&lt;10% CD20\n                    <jats:sup>+<\/jats:sup>\n                    cells) or RNA sequencing (messenger RNA &lt;\u2009500 transcripts per million) could achieve CR. Median progression\u2010free survival was 27.8 months (95% CI 23.0\u2013NE) in patients with CR and not reached in those with undetectable circulating tumor DNA at Week 12. Treatment\u2010emergent adverse events (TEAEs) led to treatment discontinuation in 16.0% of patients with CR; the most common TEAE was cytokine release syndrome (56.4%). This generally manageable safety profile and the sustainability of CRs support odronextamab as a potential long\u2010term treatment for heavily pretreated R\/R FL.\n                  <\/jats:p>","DOI":"10.1002\/hem3.70300","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:23:54Z","timestamp":1776399834000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R\/R FL) treated with odronextamab in the ELM\u20102 study"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2285","authenticated-orcid":false,"given":"Stefano","family":"Luminari","sequence":"first","affiliation":[{"name":"Hematology Unit, Azienda Unit\u00e0 Sanitaria Locale \u2013 IRCCS of Reggio Emilia  Reggio Emilia Italy"},{"name":"Oncology Department University of Modena and Reggio Emilia Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jim\u00e9nez\u2010Ubieto","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital Universitario 12 de Octubre Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Clinical Haematology Olivia Newton\u2010John Cancer Wellness &amp; Research Centre, Austin Hospital Heidelberg Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tucker","sequence":"additional","affiliation":[{"name":"Haematology Department Royal Cornwall Hospital Truro United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Ambati","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinjune","family":"Lin","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurriaan","family":"Brouwer\u2010Visser","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetachi Akunna","family":"Otele","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Antico","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose C.","family":"Villasboas","sequence":"additional","affiliation":[{"name":"Hematology Mayo Clinic Rochester Minnesota United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"KasebH AliMA GasalbertiDP KoshyNV. StatPearls [Internet]. Accessed March 31 2025.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538206\/"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281421"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624288"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013437"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180088"},{"key":"e_1_2_13_9_1","unstructured":"SinghD SinghA MukkamallaSKR. Relapsed and refractory follicular lymphoma. StatPearls [Internet]. 2023. Updated January 15 2023. Accessed May 2 2025.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK589677\/#:~:text=Follicular%20lymphoma%20is%20an%20incurable for%20relapsed\/refractory%20follicular%20lymphoma"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209932"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.248"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"issue":"2","key":"e_1_2_13_13_1","first-page":"97","article-title":"Follicular lymphoma: a focus on current and emerging therapies","volume":"36","author":"Cahill KE","year":"2022","journal-title":"Oncology (Williston Park, N.Y.)"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00989-w"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13212"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"e_1_2_13_20_1","unstructured":"European Medicines Agency. Ordspono summary of product characteristics. Accessed May 2 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ordspono-epar-product-information_en.pdf"},{"key":"e_1_2_13_21_1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow SH","year":"2017"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008338"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00981-w"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15805"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025454"},{"issue":"1","key":"e_1_2_13_28_1","first-page":"288","article-title":"Mosunetuzumab demonstrates clinically meaningful outcomes in high\u2010risk patients with heavily pre\u2010treated R\/R FL after \u22653 years of follow\u2010up: subgroup analysis of a pivotal phase II study","volume":"8","author":"Assouline S","year":"2024","journal-title":"HemaSphere"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"issue":"1","key":"e_1_2_13_30_1","first-page":"5666","article-title":"How time spent on rituximab infusion impacts patient satisfaction, stress, employment, and caregiver burden","volume":"130","author":"Fisher MD","year":"2017","journal-title":"Blood"},{"issue":"4","key":"e_1_2_13_31_1","first-page":"1101","article-title":"Predictive significance of the cut\u2010off value of CD20 expression in patients with B\u2010cell lymphoma","volume":"24","author":"Horvat M","year":"2010","journal-title":"Oncol Rep"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177469"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022348"},{"key":"e_1_2_13_34_1","unstructured":"LuminariS Brouwer\u2010VisserJ FiaschiN et al. CD20 expression and response to odronextamab: biomarker analysis in patients with relapsed\/refractory B\u2010cell non\u2010Hodgkin lymphoma (R\/R B\u2010NHL) from the ELM\u20102 study. Poster P1246 presented at: European Hematology Association (EHA); June 13\u201016 2024; Madrid Spain."},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183390"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19503"},{"key":"e_1_2_13_37_1","doi-asserted-by":"crossref","unstructured":"FalchiL RahmanJ MelendezL et al. Intratumoral T\u2010cell composition predicts epcoritamab\u2010based treatment efficacy in B\u2010cell non\u2010Hodgkin lymphomas.medRxiv. Preprint. 2024:2024.2007.2002.24309792.","DOI":"10.1101\/2024.07.02.24309792"},{"key":"e_1_2_13_38_1","doi-asserted-by":"crossref","unstructured":"BirhirayRE LuminariS KimTM et al. Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA\u20101). Poster TPS7096 presented at: American Society of Clinical Oncology (ASCO); May 31\u2010June 4 2024; Chicago IL USA.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7096"},{"key":"e_1_2_13_39_1","doi-asserted-by":"crossref","unstructured":"ChongG HawkesEA KimTM et al. Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard\u2010of\u2010care (SOC) therapy in relapsed\/refractory (R\/R) aggressive B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL; OLYMPIA\u20104). Poster TPS7093 presented at: American Society of Clinical Oncology (ASCO); May 31\u2010June 4 2024; Chicago IL USA.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7093"},{"key":"e_1_2_13_40_1","doi-asserted-by":"crossref","unstructured":"HardinC GrayC NovelliS et al. Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA\u20102). Poster TPS7099 presented at: American Society of Clinical Oncology (ASCO); May 31\u2010June 4 2024; Chicago IL USA.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7099"},{"key":"e_1_2_13_41_1","doi-asserted-by":"crossref","unstructured":"MatasarM TurgutB TessoulinB et al. Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B\u2010cell lymphoma (DLBCL; OLYMPIA\u20103). Abstract TPS7086 presented at American Society of Clinical Oncology (ASCO); May 31\u2010June 4 2024; Chicago IL USA.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7086"},{"key":"e_1_2_13_42_1","doi-asserted-by":"crossref","unstructured":"VitoloU MerliM NorasetthadaL et al. Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed\/refractory (R\/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA\u20105). Poster TPS7094 presented at: American Society of Clinical Oncology (ASCO); May 31\u2010June 4 2024; Chicago IL USA.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7094"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000312"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016332"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200623"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15020051"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7049"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70300","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:12:34Z","timestamp":1777371154000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/hem3.70300"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70300","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70300"}}